LINC00526: A Potential Drug Target for Cancer (G147525)

Target Name: LINC00526

NCBI ID: G147525

LINC00526

Other Name(s): TP53LC13 | long intergenic non-protein coding RNA 526 | Long intergenic non-protein coding RNA 526 | HsT959 | C18orf18

LINC00526: A Potential Drug Target for Cancer

LINC00526 (TP53LC13) is a protein that is expressed in various tissues of the body, including the brain, lung, heart, and gastrointestinal tract. It is a member of the TP53 gene family, which is known for its role in regulating DNA repair and cell survival. LINC00526 is a potential drug target (or biomarker) because it has been shown to promote the growth and survival of cancer cells, and it is also expressed in tissues that are often affected by cancer.

The TP53 gene is a tumor suppressor gene that is located on chromosome 17. It is responsible for producing a protein that plays a critical role in regulating DNA repair and cell survival. This protein is known as the tumor suppressor protein TP53, and it is found in all living cells. TP53 helps to ensure that the genetic material of cells is replicated correctly, and it also helps to repair any mistakes that may occur during the DNA replication process.

LINC00526 is a 21-kDa protein that is expressed in various tissues of the body. It is found in the brain, lung, heart, and gastrointestinal tract, and it is also expressed in the testes and ovaries. LINC00526 is a member of the TP53 gene family, and it is shown to promote the growth and survival of cancer cells.

One of the ways that LINC00526 promotes the growth and survival of cancer cells is by inhibiting the activity of the tumor suppressor protein TP53. TP53 is a critical regulator of cell survival, and it is shown to promote the growth and survival of cancer cells by inhibiting the activity of p53, a protein that is responsible for cell death. LINC00526 is able to inhibit the activity of TP53 by binding to its active site, which is located on the protein's amino acid residues.

Another way that LINC00526 promotes the growth and survival of cancer cells is by promoting the formation of blood-brain barrier (BBB). The BBB is a barrier that separates the brain from the blood, and it helps to protect the brain from the harmful effects of drugs and other substances that are harmful to the brain. LINC00526 is shown to promote the formation of the BBB by increasing the expression of genes that are involved in the formation of the barrier.

In addition to its role in promoting the growth and survival of cancer cells, LINC00526 is also shown to have potential as a drug target. LINC00526 has been shown to interact with several different proteins, including the protein kinase A1 (PPKG1), which is a key regulator of cell growth and survival. This suggests that LINC00526 may be a useful target for drugs that are designed to inhibit the activity of PPKG1.

In conclusion, LINC00526 is a protein that is expressed in various tissues of the body, including the brain, lung, heart, and gastrointestinal tract. It is a member of the TP53 gene family, and it is shown to promote the growth and survival of cancer cells. LINC00526 may be a useful drug target (or biomarker) because it has been shown to interact with several different proteins, including the protein kinase A1 (PPKG1), which is a key regulator of cell growth and survival. Further research is needed to fully understand the role of LINC00526 in cancer biology, and to determine the most effective way to use it as a drug.

Protein Name: Long Intergenic Non-protein Coding RNA 526

The "LINC00526 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00526 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets